Active Filter(s):
Details:
The collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 04, 2023
Details:
The partnership combines Absci’s de novo AI Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.
Lead Product(s): De novo Therapeutic Antibody
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Almirall
Deal Size: $650.0 million Upfront Cash: Undisclosed
Deal Type: Partnership November 14, 2023
Details:
Under the collaboration, Absci will deploy its Bionic Protein™ non-standard amino acid technology to produce enzymes tailored to Merck’s biomanufacturing applications and receive an upfront and certain other milestone payments.
Lead Product(s): Enzyme
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: $610.0 million
Deal Type: Collaboration January 07, 2022
Details:
Under the terms of the agreement AbSci will prepare the hAFP producing E. coli strain for transfer to Alpha Cancer Technologies' CMO of choice for commercial production.
Lead Product(s): Recombinant Human Alpha-fetoprotein
Therapeutic Area: Immunology Product Name: ACT-101
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Alpha Cancer Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 22, 2020